Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Gemma A, et al. Among authors: nakagawa k. Cancer Sci. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550. Cancer Sci. 2014. PMID: 25287435 Free PMC article. Clinical Trial.
Mutational analysis of the beta-tubulin gene in lung cancer.
Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, Nakagawa K. Tsurutani J, et al. Among authors: nakagawa k. Lung Cancer. 2002 Jan;35(1):11-6. doi: 10.1016/s0169-5002(01)00291-4. Lung Cancer. 2002. PMID: 11750707
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells.
Komiya T, Fusetani N, Matsunaga S, Kubo A, Kaye FJ, Kelley MJ, Tamura K, Yoshida M, Fukuoka M, Nakagawa K. Komiya T, et al. Among authors: nakagawa k. Cancer Chemother Pharmacol. 2003 Mar;51(3):202-8. doi: 10.1007/s00280-002-0558-8. Epub 2003 Jan 14. Cancer Chemother Pharmacol. 2003. PMID: 12655437
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Fukuoka M, et al. Among authors: nakagawa k. J Clin Oncol. 2003 Jun 15;21(12):2237-46. doi: 10.1200/JCO.2003.10.038. Epub 2003 May 14. J Clin Oncol. 2003. PMID: 12748244 Clinical Trial.
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H. Nishiwaki Y, et al. Among authors: nakagawa k. Gan To Kagaku Ryoho. 2004 Apr;31(4):567-73. Gan To Kagaku Ryoho. 2004. PMID: 15114701 Clinical Trial. Japanese.
[Gefitinib in non-small cell lung cancer].
Nakagawa K. Nakagawa K. Nihon Rinsho. 2004 Jul;62(7):1312-20. Nihon Rinsho. 2004. PMID: 15283149 Review. Japanese. No abstract available.
4,794 results